DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy.
Honoka ObataMikako OgawaMichael R ZalutskyPublished in: Pharmaceutics (2023)
The present review aims to explore the potential targets/partners for future targeted radionuclide therapy (TRT) strategies, wherein cancer cells often are not killed effectively, despite receiving a high average tumor radiation dose. Here, we shall discuss the key factors in the cancer genome, especially those related to DNA damage response/repair and maintenance systems for escaping cell death in cancer cells. To overcome the current limitations of TRT effectiveness due to radiation/drug-tolerant cells and tumor heterogeneity, and to make TRT more effective, we propose that a promising strategy would be to target the DNA maintenance factors that are crucial for cancer survival. Considering their cancer-specific DNA damage response/repair ability and dysregulated transcription/epigenetic system, key factors such as PARP, ATM/ATR, amplified/overexpressed transcription factors, and DNA methyltransferases have the potential to be molecular targets for Auger electron therapy; moreover, their inhibition by non-radioactive molecules could be a partnering component for enhancing the therapeutic response of TRT.
Keyphrases
- dna damage response
- dna repair
- papillary thyroid
- dna damage
- cell death
- squamous cell
- transcription factor
- randomized controlled trial
- single molecule
- circulating tumor
- induced apoptosis
- cell cycle arrest
- cancer therapy
- cell free
- stem cells
- dna methylation
- oxidative stress
- hiv testing
- genome wide
- drug delivery
- dna binding
- young adults
- hepatitis c virus